Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Benzinga
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on DCOY
About DCOY
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
- vTv Therapeutics Rating: Roth Capital analyst Adam Walsh initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $58, indicating significant upside potential from its current price of $33.54.
- MasTec Upgrade: Cantor Fitzgerald analyst Manish Somaiya initiated coverage on MasTec Inc (NYSE:MTZ) with an Overweight rating and a price target of $274, suggesting strong market optimism given its current price of $244.57.
- e.l.f. Beauty Analysis: Citigroup analyst Filippo Falorni initiated coverage on e.l.f. Beauty Inc (NYSE:ELF) with a Buy rating and a price target of $110, reflecting confidence in the brand's growth potential from its current price of $95.34.
- Decoy Therapeutics Outlook: Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on Decoy Therapeutics Inc (NASDAQ:DCOY) with a Buy rating and a price target of $2.5, indicating positive expectations for its market performance from its current price of $0.7505.
Continue Reading
Decoy Therapeutics Secures Gates Foundation Funding to Advance Global Manufacturing of Antivirals
- Global Manufacturing Platform: Decoy Therapeutics, funded by the Gates Foundation, is developing a flexible global manufacturing platform aimed at providing antiviral drugs to low- and middle-income countries, which is expected to significantly enhance these regions' ability to respond to emerging pathogens.
- Rapid Response Capability: The platform will establish a distributed manufacturing network capable of quickly responding to viral outbreaks worldwide, enhancing Decoy's commercial competitiveness in global markets while supporting future production of antiviral drugs.
- Technological Innovation: Decoy's IMP3ACT platform leverages machine learning and AI to rapidly design and manufacture peptide-conjugate antivirals with broad activity, with plans to advance its lead asset targeting coronaviruses and file an IND application with the FDA within the next 12 months.
- Multi-Domain Drug Development: In addition to coronavirus treatments, Decoy plans to develop broad-spectrum antivirals for flu, COVID-19, and RSV, as well as peptide-drug conjugates targeting gastrointestinal cancers, showcasing its potential across multiple therapeutic areas.
Continue Reading